Bio-energy in Wan Tai rose to 65,438+0,000 yuan, and Wan Tai Bio was founded at 65,438+09,965,438+0, with its headquarters in Beijing, mainly engaged in the research, development, production and sales of in vitro diagnostic reagents, in vitro diagnostic instruments and vaccines. 2020 is an "important year" for biology in Wan Tai. On February 30th, 2065438+0918, the bivalent cervical cancer (HPV2) vaccine developed by Wan Tai Biotechnology Company was officially approved for marketing by the US Food and Drug Administration, breaking the monopoly of imported vaccines in China, becoming the third bivalent cervical cancer vaccine in the world and the first and only vaccine approved for marketing in China. The vaccine was officially launched in May 2020. At the beginning of 2020, faced with the sudden outbreak of COVID-19, Wan Tai Biotechnology quickly launched a self-developed COVID-19 virus detection reagent, which was approved for listing in March 2020 and played an important role in epidemic prevention and anti-epidemic. At the same time, Wan Tai's biological nine-valent HPV vaccine has entered the second clinical phase, which is the second domestic nine-valent HPV vaccine in the world and the first vaccine to apply for clinical trials in China.

The "track" is good, with many exclusive technologies and great imagination. Such companies are naturally sought after by investors. On April 29th, 2020, Wan Tai Bio was listed on the main board of Shanghai Stock Exchange, with 26 consecutive daily limit. The stock price rose from the opening price 12.6 yuan to 296.8 yuan. By the end of last year, the share price was 20 1.53 yuan, with an annual increase of 1.499%, which was one of the main "monster stocks" of that year.

：

Please click to enter the picture description (maximum 18 words).

Behind the skyrocketing stock price is the soaring performance of the company. 65438 This year1October 20th, Wan Tai Bio announced that its net profit will increase by 2 15% to 244% in 2020. The top two sources of performance growth are HPV2 and COVID-19 detection reagents, and "sales revenue and profits have increased significantly". On June 365438+February 3, 20201day, Wan Tai Bio announced that the nasal spray influenza virus carrier COVID-19 vaccine developed by the company in cooperation with Xiamen University and Hong Kong University has entered the second phase of clinical trials. This heavy news further stimulated the stock price to rise. As of this year's 1 close, the company's share price is 324 yuan.

Beijing Wan Tai Bio-Pharmaceutical Co., Ltd. is a high-tech enterprise engaged in the research and development and production of bio-diagnostic reagents and vaccines, with the concept of "science-oriented, health-oriented", the purpose of "quality for survival, scientific and technological innovation for development" and the pursuit of "contributing to human health", and transforming biotechnology achievements into high-quality products to serve the public.